Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | Joaquin Mateo, S. Sandhu, S. Miranda, S. Carreira, S. Jain, C. Ralph, A. Protheroe, S. Hussain, R. Jones, T. Elliot, U. McGovern, A. Gillman, C. Paulding, H. Mossop, N.Porta, D. Bianchini, Z. Zafeiriou, G.Boysen, D. N. Rodrigues, et. al. | ||||||||||||
Title | DNA repair defects and antitumor activity with PARP inhibition: TOPARP, a phase II trial of olaparib in metastatic castration resistant prostate cancer | ||||||||||||
|
|||||||||||||
URL | http://cancerres.aacrjournals.org/content/75/15_Supplement/CT322.short | ||||||||||||
Abstract Text | doi: 10.1158/1538-7445.AM2015-CT32 Cancer Res August 1, 2015 75; CT322 |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
ATM mutant | prostate cancer | sensitive | Olaparib | Phase II | Actionable | In a Phase II clinical trial, 80% (4/5) of metastatic castration-resistant prostate cancer patients with ATM truncation mutations demonstrated response to Lynparza (olaparib) treatment (Cancer Res August 1, 2015 75:CT322). | detail... |